Table 1 Randomized trials of maintenance... | American Society of Hematology

Table 1

Randomized trials of maintenance vs observation (group 1 studies)

Reference	No. of patients*	Age (y)	Regimen
Immunotherapy
22	41	NA	BCG + irradiated allogeneic myeloblasts vs observation
16	45	15-59	IFN-α vs chemotherapy (3 y) vs observation
10	163	≥60	IL-2 (3 mo) vs observation
21†	528	≤60	IL-2 (1 y) vs observation
17	161	50-70	IL-2 (1 y) vs observation
19	154	0-18	IL-2 (1 y) vs observation
Conventional chemotherapy
20	74	7-65	Chemotherapy (2 y) vs observation
11	145	≥15	Chemotherapy (3 y) vs observation
13	48	18-75	Chemotherapy (6 mo) vs observation
15	147	≥60	Chemotherapy (1 y) vs observation
18	70	<20	Chemotherapy (1.5 y) vs observation
Other approaches
14	102	>60	Cytarabine + all-trans retinoic acid (1 y) vs observation
12	226	>60	Azacitidine (1 y) vs observation

Reference	No. of patients*	Age (y)	Regimen
Immunotherapy
22	41	NA	BCG + irradiated allogeneic myeloblasts vs observation
16	45	15-59	IFN-α vs chemotherapy (3 y) vs observation
10	163	≥60	IL-2 (3 mo) vs observation
21†	528	≤60	IL-2 (1 y) vs observation
17	161	50-70	IL-2 (1 y) vs observation
19	154	0-18	IL-2 (1 y) vs observation
Conventional chemotherapy
20	74	7-65	Chemotherapy (2 y) vs observation
11	145	≥15	Chemotherapy (3 y) vs observation
13	48	18-75	Chemotherapy (6 mo) vs observation
15	147	≥60	Chemotherapy (1 y) vs observation
18	70	<20	Chemotherapy (1.5 y) vs observation
Other approaches
14	102	>60	Cytarabine + all-trans retinoic acid (1 y) vs observation
12	226	>60	Azacitidine (1 y) vs observation

Positive trials are shown in bold.

NA, not available.

Randomly assigned between maintenance and observation arms.

Maintenance randomization occurred after 1 cycle of consolidation and auto-HCT.